- Home
- AVTX vs IPSC Comparison
AVTX vs IPSC Comparison
Compare AVTX & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- IPSC
- Stock Information
- Founded
- AVTX 2011
- IPSC 2019
- Country
- AVTX United States
- IPSC United States
- Employees
- AVTX N/A
- IPSC N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- AVTX Health Care
- IPSC Health Care
- Exchange
- AVTX Nasdaq
- IPSC Nasdaq
- Market Cap
- AVTX 57.4M
- IPSC 48.2M
- IPO Year
- AVTX 2015
- IPSC 2021
- Fundamental
- Price
- AVTX $4.13
- IPSC $0.54
- Analyst Decision
- AVTX Strong Buy
- IPSC Strong Buy
- Analyst Count
- AVTX 6
- IPSC 5
- Target Price
- AVTX $34.20
- IPSC $3.33
- AVG Volume (30 Days)
- AVTX 62.6K
- IPSC 719.1K
- Earning Date
- AVTX 05-12-2025
- IPSC 05-15-2025
- Dividend Yield
- AVTX N/A
- IPSC N/A
- EPS Growth
- AVTX N/A
- IPSC N/A
- EPS
- AVTX N/A
- IPSC N/A
- Revenue
- AVTX $441,000.00
- IPSC $114,898,000.00
- Revenue This Year
- AVTX N/A
- IPSC $833.10
- Revenue Next Year
- AVTX N/A
- IPSC N/A
- P/E Ratio
- AVTX $0.59
- IPSC N/A
- Revenue Growth
- AVTX N/A
- IPSC 8286.72
- 52 Week Low
- AVTX $3.39
- IPSC $0.34
- 52 Week High
- AVTX $16.00
- IPSC $3.46
- Technical
- Relative Strength Index (RSI)
- AVTX 45.63
- IPSC 47.90
- Support Level
- AVTX $3.43
- IPSC $0.53
- Resistance Level
- AVTX $4.03
- IPSC $0.59
- Average True Range (ATR)
- AVTX 0.34
- IPSC 0.04
- MACD
- AVTX 0.09
- IPSC -0.00
- Stochastic Oscillator
- AVTX 70.47
- IPSC 37.56
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.